Adeniyi Adebesin

Dr. Adeniyi Adebesin


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JIJohn Imig
John Imig
MKMd Abdul Hye Khan
Md Abdul Hye Khan
ABAnna Burkhan
Anna Burkhan
Guan ChenGuan Chen
Guan Chen
AAAdeniyi Adebesin
Adeniyi Adebesin
JFJohn R. Falck
John R. Falck
Although epoxyeicosatrienoic acid (EET) analogs have performed well in several acute and chronic kidney disease models, targeted delivery of EET analogs to the kidney can be reasonably expected to reduce the level of drug needed to achieve a therapeutic effect and obviate possible side effects. For EET analog kidney-targeted delivery, we conjugated a stable EET analog to folic acid via a PEG-diamine linker. Next, we compared the kidney targeted EET analog, EET-F01, to a well-studied EET analog, EET-A. EET-A or EET-F01 was infused i.v. and plasma and kidney tissue collected. EET-A was detected in the plasma but was undetectable in the kidney. On the other hand, EET-F01 was detected in the plasma and kidney. Experiments were conducted to compare the efficacy of EET-F01 and EET-A for decreasing cisplatin nephrotoxicity. Cisplatin was administered to WKY rats treated with vehicle, EET-A (10 mg/kg i.p.) or EET-F01 (20 mg/kg or 2 mg/kg i.p.). Cisplatin increased kidney injury markers, viz., blood urea nitrogen (BUN), N-acetyl-β-(D)-glucosaminidase (NAG), kidney injury molecule-1 (KIM-1), and thiobarbituric acid reactive substances (TBARS). EET-F01 was as effective as EET-A in decreasing BUN, NAG, KIM-1, TBARS, and renal histological injury caused by cisplatin. Despite its almost 2×-greater molecular weight compared with EET-A, EET-F01 was comparably effective in decreasing renal injury at a 10-fold w/w lower dose. EET-F01 decreased cisplatin nephrotoxicity by reducing oxidative stress and inflammation. These data demonstrate that EET-F01 targets the kidney, allows for a lower effective dose, and combats cisplatin nephrotoxicity. In conclusion, we have developed a kidney targeted EET analog, EET-F01, that demonstrates excellent potential as a therapeutic for kidney diseases.

Verified
Journal Article
Open access
PDF file
ADAhmed Darwesh
Ahmed Darwesh
WFWesam Farag
Wesam Farag
AAAdeniyi Adebesin
Adeniyi Adebesin
AMAbdul Sattar Mohammad
Abdul Sattar Mohammad
JFJohn R. Falck
John R. Falck
JSJohn M Seubert
John M Seubert
While survival rates have markedly improved following cardiac ischemia-reperfusion (IR) injury, the resulting heart damage remains an important issue. Preserving mitochondrial quality and limiting NLRP3 inflammasome activation is an approach to limit IR injury, in which the mitochondrial deacetylase sirtuin 3 (SIRT3) has a role. Recent data demonstrate cytochrome P450 (CYP450)-derived epoxy metabolites, epoxydocosapentaenoic acids (EDPs), of docosahexaenoic acid (DHA), attenuate cardiac IR injury. EDPs undergo rapid removal and inactivation by enzymatic and non-enzymatic processes. The current study hypothesizes that the cardioprotective effects of the synthetic EDP surrogates AS-27, SA-26 and AA-4 against IR injury involve activation of SIRT3. Isolated hearts from wild type (WT) mice were perfused in the Langendorff mode with vehicle, AS-27, SA-26 or AA-4. Improved postischemic functional recovery, maintained cardiac ATP levels, reduced oxidative stress and attenuation of NLRP3 activation were observed in hearts perfused with the analogue SA-26. Assessment of cardiac mitochondria demonstrated SA-26 preserved SIRT3 activity and reduced acetylation of manganese superoxide dismutase (MnSOD) suggesting enhanced antioxidant capacity. Together, these data demonstrate that the cardioprotective effects of the EDP analogue SA-26 against IR injury involve preservation of mitochondrial SIRT3 activity, which attenuates a detrimental innate NLRP3 inflammasome response.

1 January 2024 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
JKJoshua Walter Kranrod
Joshua Walter Kranrod
ADAhmed Darwesh
Ahmed Darwesh
WFWesam Farag
Wesam Farag
AHAndy Huang
Andy Huang
LFLiye Fang
Liye Fang
JSJohn M Seubert
John M Seubert
Mounting evidence suggests that CYP epoxygenase-derived metabolites of docosahexaenoic acid, called epoxydocosapentaenoic acids (EDPs), limit mitochondrial damage following cardiac injury. In particular, the 19,20-EDP regioisomer has demonstrated potent cardioprotective action. Thus, we investigated our novel synthetic 19,20-EDP analog SA-22 for protection against cardiac IR injury. Isolated C57BL/6J mouse hearts were perfused via Langendorff apparatus for 20 minutes to obtain baseline function followed by 30 minutes of global ischemia. Hearts were then treated with either vehicle, 19,20-EDP, SA-22, or SA-22 with the pan-sirtuin inhibitor nicotinamide (NAM), or the SIRT3-selective inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) at the start of 40 minutes reperfusion (N=5-8). We assessed IR injury-induced changes in recovery of myocardial function, using left ventricular developed pressure, systolic and diastolic pressure change. Tissues were assessed for ETC function, SIRT-1 and -3, optic atrophy type-1, and caspase-1. We also utilized H9c2 cells in an in vitro model of hypoxia/reoxygenation injury (N=3-6). Hearts perfused with SA-22 had significantly improved postischemic LVDP, systolic and diastolic recovery (64% of baseline), compared to vehicle control (15% of baseline). In addition, treatment with SA-22 led to better catalytic function observed in electron transport chain and SIRT enzymes. The protective action of SA-22 resulted in reduced activation of pyroptosis in both hearts or cells following injury. Interestingly, while NAM co-treatment worsened functional outcomes, cell survival and attenuated sirtuin activity, it failed to completely attenuate SA-22-induced protection against pyroptosis, possibly indicating EDPs exert cytoprotection through pleiotropic mechanisms. In short, these data demonstrate the potential of our novel synthetic 19,20-EDP analog, SA-22, against IR/HR injury and justifies further development of therapeutic agents based upon 19,20-EDP.

3 December 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
AAAdeniyi Adebesin
Adeniyi Adebesin
RRRichard Joseph Roman
Richard Joseph Roman
WCWilliam B. Campbell
William B. Campbell
JSJohn M. Seubert
John M. Seubert
RTRheem A. Totah
Rheem A. Totah
The review by Jiang et al. discusses the cardioprotective mechanisms of epoxyeicosatrienoic acids (EETs), epoxyeicosatetraenoic acids (EEQs), and epoxydocosapentaenoic acids (EDPs), which are CYP epoxygenase metabolites of arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), respectively. Research from various laboratories suggests that these metabolites are endothelium-derived hyperpolarization factors (EDHF) involved in blood vessel vasodilation and renal tubular salt reabsorption via actions on potassium, calcium, and sodium channels. Their proposed mechanisms of action include direct binding to ion channels and indirect modulation of ion channels via G-protein and protein kinase pathways. Therefore, EET mimetics and soluble epoxide hydrolase (sEH) inhibitors, which block epoxide hydrolysis of endogenous EETs, show significant blood pressure lowering effects in various hypertensive animal models. Other notable protective effects of EETs in CVD models include: 1) pro-angiogenesis and anti-apoptosis in myocardial infarction (MI) models, 2) antiinflammation in atherosclerosis models, and 3) anti-oxidant effects and modulation of calcium homeostasis in heart failure models. The review also covers non-hydrolase functions of sEH in CVD, an often overlooked activity, as well as cell type-specific mechanisms of EETs and sEH inhibitors.In the article by Baranowska et al., the combination of low-dose (10mg/kg/day) of an orally-active, stable EET mimetic (EET-A) and a low dose (10mg/kg/day) of AAA, a 20-hydroxyeicosatetraenoic acid (20-HETE) antagonist, was shown to provide superior blood pressure lowering effect than a higher dose (40 mg/kg/day) of EET-A alone in a spontaneously hypertensive rat model. 20-HETE is produced by the metabolism of arachidonic acid by the CYP4A and F subfamilies and is a vasoconstrictor in various vascular beds that contributes to the development of hypertension in SHR. These results indicate a prominent role for the 20-HETE/CYP4 pathway in the vascular dysfunction in this model and suggest a promising therapeutic strategy for the treatment of hypertension, which warrants additional investigation.Helal et al. assessed the effects of individual (R/S)-enantiomers of 11-hydroxyeicosatetraenoic acid (11-HETE) on CYP1B1 activity and cellular hypertrophy in RL-14 cardiomyocyte cells. 11-HETE is an arachidonic acid metabolite produced by CYPs, cyclooxygenase (COX 1/2) enzymes, and non-enzymatic oxidative processes. Both enantiomers increased cardiomyocyte hypertrophy but only the 11(S)enantiomer increased CYP1B1 activity. Interestingly, the 11-(S)-enantiomer increased the mRNA and protein expression of both cardioprotective CYP2J and pro-inflammatory 20-HETE producing CYP4F2, while the 11(R)-enantiomer did not increase CYP2J levels. These results are consistent with previous work by the El-Kadi group on the differential effects of HETE enantiomers on CYP expression and activity that suggest the existence of distinct binding sites/receptors for each enantiomer. Other potential implications include: 1) a positive fed-back loop in the 11-HETE/CYP1B1 axis could exacerbate cardiac hypertrophy, 2) secondary metabolism of eicosanoids by 11-HETE induced CYPs might be relevant in cardiac hypertrophy, and 3) CYP expression and activity may encompass an equilibrium between antiand pro-inflammatory eicosanoids, which potentially become skewed during oxidative stress or in diseased states. Strategies to restore the normal equilibrium between these isoforms might provide safer, more effective treatments for CVD.Finally, using a multidisciplinary approach, Chu et al. elucidated the antihypertensive mechanism of action of tetrandrine, a bioactive alkaloid component of Stephania tetrandra S Moore root (Fang Ji), a traditional Chinese medicine used for decades for its diuretic and antihypertensive actions. They also demonstrated that chronic administration of tetrandrine (30 and 60 mg/Kg/day) to SHR was as effective as spironolactone (20 mg/Kg/day) in increasing sodium excretion and lowering blood pressure in spontaneously hypertensive rats. This work identifies tetrandrine as a diuretic that covalently binds to CYP11A1 in an unconventional way to inhibit aldosterone biosynthesis. The proposed mechanism should help researchers/clinicians understand its pharmacological effects and to explore future therapeutic applications, particularly for heart failure. Future work should investigate the inhibition of other CYPs by tetrandrine.In summary, the articles in this RT contribute to our understanding of the roles of CYPs, their metabolites and modulators in CVD. The discoveries from these outstanding laboratories contained in this RT will stimulate further research on these topics and spawn additional innovative ideas and therapies to improve cardiovascular health.

4 September 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
HWHaoying Wu
Haoying Wu
AAAdeniyi Adebesin
Adeniyi Adebesin
JFJohn R. Falck
John R. Falck
XXXinyun Xu
Xinyun Xu
JCJiangang Chen
Jiangang Chen
Ling ZhaoLing Zhao
Ling Zhao

26 May 2026 in European Journal of Organic Chemistry
Verified
Journal Article
Open access
RARaghunath Reddy Anugu
Raghunath Reddy Anugu
JFJohn R. Falck
John R. Falck
AAAdeniyi Adebesin
Adeniyi Adebesin
Iminodirhodium and iminocopper electrophilic intermediates, generated in situ from O ‐mesylacetoxime using catalytic Rh 2 (esp) 2 and Cu(I)Br, respectively, are versatile reagents for selective intermolecular CH activation. These reagents oxidize alcohols and aldehydes with the convenience and mildness of contemporary oxidants while improving atom‐efficiency, isolation, and economy. Mechanistic studies suggest an electrophilic, α‐oxy hydride abstraction thus establishing these iminometallic species as a new class of hydride abstractors.